Unrelated donor marrow transplantation in children: Transplant policy and outcome in Leiden Paediatrics SCT-Centre

Bone Marrow Transplantation

Volumn 45, Issue 1, 2010, Pages 87-95

  Vossen, J M ^a   Donker, A E ^a   Heemskerk, M B A ^a,b   Lie, J L W T J ^b   Van Weel Sipman, M H ^a   Bredius, R G M ^a   Bakker, J D J ^a   Egeler, R M ^a   Oudshoorn, M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Europdonor Foundation   (Netherlands)

Author keywords

BMT; Children; Permissible mismatches; Unrelated donor

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; CYCLOSPORIN A; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; METHOTREXATE; ODULIMOMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; CANCER RELAPSE; CHEMOPROPHYLAXIS; CHILD; CHILDHOOD CANCER; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; DONOR SELECTION; ENGRAFTMENT; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEALTH CARE POLICY; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NETHERLANDS; OVERALL SURVIVAL; PATIENT CARE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEALTH POLICY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; PATIENT ISOLATION; RETROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 75149149112     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.104     Document Type: Article

References (64)

1. Vossen JM. Bone Marrow Transplantation in children. Bailliè re's Clin. Paediatrics 1994; 1: 1029-1059.
2. Sanders JE. Bone Marrow Transplantation for pediatric malignancies. Pediatr Clin North Am 1997; 44: 1005-1020.
3. Horwitz ME. Stem-cell transplantation for inherited immunodeficiency disorders. Pediatr Clin North Am 2000; 47: 1371-1387.
4. Reiss U, Bolotin E. New approaches to hematopoietic cell transplantation in oncology. Pediatr Clin North Am 2002; 49: 1437-1466.
5. Oudshoorn M, Van Leeuwen A, Van der Zanden HGM, van Rood JJ. on behalf of the Editorial Board of BMDW. Bone marrow donors worldwide. A successful exercise in international cooperation. Bone Marrow Transplant 1994; 14: 3-8.
6. Oudshoorn M, Cornelissen JJ, Fibbe WE, Graeff-Meerder ER, Lie JL, Schreuder GM et al. Problems and possible solutions in finding an unrelated bone marrow donor. Results of consecutive searches for 240 Dutch patients. Bone Marrow Transplant 1997; 20: 1011-1017.
7. Oudshoorn M, van Walraven SM, Bakker JNA, Lie JL, Zanden HG VD, Heemskerk MB et al. Hematopoietic stem cell donor selection: the Europdonor experience. Human Immunol 2006; 67: 405-412.
8. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility and engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
9. Green A, Clarke E, Hunt L, Canterbury A, Lankester A, Hale G et al. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors, have an increased incidence of primary graft failure but a similar overall transplant outcome. Blood 1999; 94: 2236-2246.
10. Hansen JA, Yamamoto K, Petersdorf E, Sasazuki T. The role of HLA matching in hematopoietic cell transplantation. Rev Immunogen 1999; 1: 359-373.
11. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001; 345: 1794-1800.
12. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562. (Pubitemid 20069191)
13. Keuning JJ, Termijtelen A, Blussévan Oud Alblas A, van den Tweel JG, Schreuder I, van Rood JJ. Typing for MLC(LD). Transplant Proc 1975; 7: 35-39.
14. Kaminski E, Sharrock C, Hows J, Ritter M, Arthur C, McKinnon S et al. Frequency analysis of cytotoxic T-lymphocyte precursors: possible relevance to HLA-matched unrelated donor bone marrow transplantation. Bone Marrow Transplant 1988; 3: 149-155.
15. Zhang L, Li SG, Vandekerckhove B, Termijtelen A, van Rood JJ, Claas FH. Analysis of cytotoxic T cell precursor frequencies directed against individual HLA-A and-B alloantigens. J Immunol Methods 1989; 121: 39-45.
16. Wagemaker G, Heidt PJ, Merchov S, van Bekkum DW. Abrogation of histo-incompatibility barriers in Rhesus monkeys. In: Baum SJ, Ledney GD, Thierfelder S (eds). Experimental Haematology Today. Karger: Basel, 1982, pp 111-118.
17. Slaper-Cortenbach IC, Wijngaarden-du Bois MJ, Vries-van Rossen A, Borst HP, van der Lelie H, van Heugten HG et al. The depletion of T cells from haematopoietic stem cell transplants. Rheumatology (Oxford) 1999; 38: 751-754.
18. Hale G, Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994; 3: 15-31.
19. Vossen JM, van de Waaij D. Reverse isolation in bone marrow transplantation; ultra-clean room compared with laminar flow technique I. Isolation systems. Eur J Clin Biol Res 1972; 17: 457-461.
20. Vossen JM, Heidt PJ, van den Berg H, Gerritsen EJ, Hermans J, Dooren LJ. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990; 9: 14-23.
21. Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporin, methotrexate and prednisone. Blood 1995; 86: 1228-1234.
22. Hansen JA, Petersdorf E, Martin PJ, Anasetti C. Hematopoietic stem cell transplants from unrelated donors. Immunol Rev 1997; 157: 141-151.
23. Sasazuki T, Juji T, Morishima Y, Kinukawa H, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998; 339: 1177-1185.
24. El Kassar N, Legouvello S, Joseph CM, Salesses P, Rieux C, Cordonnier C et al. High resolution HLA class I and II typing and CTLp frequency in unrelated donor transplantation: a single-institution retrospective study of 69 BMTs. Bone Marrow Transplant 2001; 27: 35-43.
25. Oudshoorn M, Doxiadis II, van den Berg-Loonen PM, Voorter CE, Verduyn W, Claas FH. Functional versus structural matching: can the CTLp test be replaced by HLA allele typing ? Hum Immunol 2002; 63: 176-184.
26. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
27. Balduzzi A, Gooley T, Anasetti C, Sanders JE, Martin PJ, Petersdorf EW et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
28. Kollman C, Howe CWS, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-2051.
29. Woolfrey AE, Anasetti C, Storer B, Doney K, Milner LA, Sievers EL et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002; 99: 2002-2008.
30. Dominietto A, Lamparelli T, Raiola AM, van Lint MT, Gualandi F, Berisso G et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100: 3930-3934.
31. Broers AE, van der Holt R, van Essen JW, Gratama JW, Henzen-Logmans S, Kuenen-Bouwmeester V et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell depleted stem cell transplantation. Blood 2000; 95: 2240-2245.
32. Kröger N, Zabelina T, Krüger W, Renges H, Stute M, Schrum J et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Hematol 2001; 113: 1060-1071.
33. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and pre-emptive therapy. Blood 2004; 103: 2003-2008.
34. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-630.
35. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201-1207.
36. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perze WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-585.
37. Smith FO, King R, Nelson G, Wagner JE, Robertson KA, Sanders JE et al. Unrelated donor marrow transplantation for children with juvenile myelomonocytic leukemia. Br J Haematol 2002; 116: 716-724. (Pubitemid 34178679)
38. Korthof ET, Snijder PP, de Graaf AA, Lankester AC, Bredius RG, Ball LM et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. Bone Marrow Transplant 2005; 35: 455-461.
39. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
40. Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003; 102: 1224-1231.
41. Nemecek ER, Gooley TA, Woolfrey AE, Carpenter PA, Matthews DC, Sanders JE. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant 2004; 34: 799-806.
42. Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukemia: the MRC UKALL X experience. Br J Haematol 1998; 101: 94-103.
43. Souillet G, Rey S, Bertrand Y, Pujol M, Pondarre C, Bourgeot JP et al. Outcome of unrelated bone marrow donor searches in 174 children resulting in 45 patients transplanted in the HLAmatched and-mismatched situation. Bone Marrow Transplant 2000; 26: 31-43.
44. Leung WH, Turner V, Richardson SL, Benaim E, Hale G, Horwitz EM et al. Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 2001; 62: 399-407.
45. Dini G, Cancedda R, Giorgiani G, Porta F, Messina C, Uderzo C et al. Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO). Haematologica 2002; 87(8 Suppl): 51-57.
46. Giebel S, Giorgiani G, Martinetti M, Zecca M, Maccario R, Salvaneschi L et al. Low incidence of severe acute graft-versushost disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transplant 2003; 31: 987-993.
47. Dini G, Cancedda R, Locatelli F, Bosi A, Bandini G, Alessandrino EP et al. Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO). Haematologica 2001; 86: 451-456.
48. Yumura-Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, Sawada A et al. Unrelated donor bone marrow transplantation for 100 pediatric patients: a single institute's experience. Bone Marrow Transplant 2005; 36: 307-313.
49. Niesters HG. Clinical virology in real time. J Clin Virol 2002; 25(Suppl 3): S3-S12.
50. Gerritsen EJA, Stam ED, Hermans J, Van den Berg H, Haraldsson A, Van Tol MJD et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377-382.
51. Beelen DW, Elmaagacli A, Müller K-D, Hirche H, Schaefer UW. Influence of bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: Final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267-3275.
52. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
53. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
54. Heemskerk MB, Cornelissen JJ, Roelen DL, van Rood JJ, Claas FH, Doxiadis et al. Highly diverged MHC class I mismatches are acceptable for haematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 193-200.
55. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-1930.
56. Loiseau P, Esperou H, Busson M, Sghiri R, Tamouza R, Hilarius M et al. DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation. Bone Marrow Transplant 2002; 30: 497-502.
57. Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271-280.
58. Shaw BE, Potter MN, Mayor NP, Pay AL, Smith C, Goldman JM et al. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1001-1008.
59. Giebel S, Locatelli F, Wojnar J, Velardi A, Mina T, Giorgiani G et al. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2005; 131: 483-486.
60. Shaw BE, Gooley T, Madrigal JA, Malkki M, Marsh SG, Petersdorf EW. Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. Tissue Antigens 2007; 69(Suppl 1): 36-41.
61. Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007; 13: 315-328.
62. Dini G, Lanino E, Lamparelli T, Barbanti M, Sacchi N, Carcassi C et al. Unrelated donor marrow transplantation: Initial experience of the Italian bone marrow transplant group (GITMO). Bone Marrow Transplant 1996; 17: 55-62.
63. Heemskerk MB, van Walraven SM, Cornelissen JJ, Barge RM, Bredius RG, Egeler RM et al. How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more. Bone Marrow Transplant 2005; 35: 645-652.
64. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003; 101: 4233-4244.